OCT Agreement and Precision Study

NCT02045823 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2022-06-08

No results posted yet for this study

Summary

To demonstrate clinical substantial equivalence of 3D OCT-1 Maestro as comparable to the commercially available iVue and NW-300. Also, to demonstrate clinical substantial equivalence of 3D OCT-2000 Maestro as comparable to the commercially available NW-300.

Conditions

  • Normal Eyes
  • Eyes With Glaucoma
  • Eyes With Retinal Disease

Sponsors & Collaborators

  • Topcon Medical Systems, Inc.

    lead INDUSTRY

Principal Investigators

  • Mike Sinai, PhD · Topcon Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02045823 on ClinicalTrials.gov